Xiaochu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaochu Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Caiyuan Chen
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
1 shared publicationJinlong Li
Ganzhou Liver Institute, Ganzhou Fifth People’s Hospital, Ganzhou, China
1 shared publicationLeying Lin
School of Basic Medicine, Gannan Medical University, Ganzhou, China
1 shared publication- Qiang Lin
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
1 shared publication Qing Wang
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
1 shared publication- Qingrong Wu
Department of Pharmacy, Ganzhou Liver Institute, Ganzhou Fifth People’s Hospital, Ganzhou, People’s Republic Of China
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by Springer Nature in Discover Oncology
The global research trends and hotspots on osteosarcopenia in aging over the past decade
- 29 October 2026
- Published by Springer Nature in Discover Oncology
Open AccessThe global research trends and hotspots on osteosarcopenia in aging over the past decade
- Open Access
- 7 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A cross-sectional study on associated factors of Chinese herbal medicine use in middle-aged and older adults with dyslipidaemia
The efficacy of Chinese herbal medicine (CHM) in treating dyslipidaemia has been demonstrated. However, the prevalence of CHM treatment and factors influencing its use in middle-aged and older patients with dyslipidaemia in China remain unclear. We aimed to investigate the prevalence and contributing factors of CHM use among middle-aged and older Chinese patients with dyslipidaemia. The data analyzed in this study were extracted from the fourth wave (2018) of the China Health and Retirement Longitudinal Study (CHARLS). Information on demographic and socioeconomic characteristics, health service use, health status, and history of CHM use was obtained. A logistic regression model was used to identify the key factors (demographics, health service use, and health status) that predict CHM use in the treatment of dyslipidaemia. In this cross-sectional study, a total of 4341 participants (middle-aged adults, 56.46%; older adults, 42.36%; males, 45.06%; females, 54.94%) with dyslipidaemia were included, and the prevalence of CHM use for dyslipidaemia was 14.08%. A logistic regression analysis revealed that compared with participants who did not use CHM, those who used CHM were more likely to have no income (OR 1.33; 95% CI 1.02, 1.74), visit traditional Chinese medicine hospitals (OR 2.85; 95% CI 1.71, 4.74), engage in self-treatment (OR 1.70; 95% CI 1.35, 2.13), report fair or poor health status (fair, OR 1.60; 95% CI 1.13, 2.26; poor, OR 1.99; 95% CI 1.36, 2.86), and a higher modified Chinese multimorbidity-weighted index (OR 1.06; 95% CI 1.03, 1.10). In the joint effect analysis, patients who visited a Chinese medicine hospital and had a stroke were more likely to use CHM (OR 6.90; 95% CI 2.08, 22.88) than those who did not visit a Chinese medicine hospital and did not have a stroke. In this study, the prevalence of CHM use was 14.08% among middle-aged and older patients with dyslipidaemia and was correlated with demographic factors, multimorbidity, and health service preferences in China. These findings suggest the need to integrate patient-specific factors into CHM-based dyslipidaemia management strategies.
- 7 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA cross-sectional study on associated factors of Chinese herbal medicine use in middle-aged and older adults with dyslipidaemia
The efficacy of Chinese herbal medicine (CHM) in treating dyslipidaemia has been demonstrated. However, the prevalence of CHM treatment and factors influencing its use in middle-aged and older patients with dyslipidaemia in China remain unclear. We aimed to investigate the prevalence and contributing factors of CHM use among middle-aged and older Chinese patients with dyslipidaemia. The data analyzed in this study were extracted from the fourth wave (2018) of the China Health and Retirement Longitudinal Study (CHARLS). Information on demographic and socioeconomic characteristics, health service use, health status, and history of CHM use was obtained. A logistic regression model was used to identify the key factors (demographics, health service use, and health status) that predict CHM use in the treatment of dyslipidaemia. In this cross-sectional study, a total of 4341 participants (middle-aged adults, 56.46%; older adults, 42.36%; males, 45.06%; females, 54.94%) with dyslipidaemia were included, and the prevalence of CHM use for dyslipidaemia was 14.08%. A logistic regression analysis revealed that compared with participants who did not use CHM, those who used CHM were more likely to have no income (OR 1.33; 95% CI 1.02, 1.74), visit traditional Chinese medicine hospitals (OR 2.85; 95% CI 1.71, 4.74), engage in self-treatment (OR 1.70; 95% CI 1.35, 2.13), report fair or poor health status (fair, OR 1.60; 95% CI 1.13, 2.26; poor, OR 1.99; 95% CI 1.36, 2.86), and a higher modified Chinese multimorbidity-weighted index (OR 1.06; 95% CI 1.03, 1.10). In the joint effect analysis, patients who visited a Chinese medicine hospital and had a stroke were more likely to use CHM (OR 6.90; 95% CI 2.08, 22.88) than those who did not visit a Chinese medicine hospital and did not have a stroke. In this study, the prevalence of CHM use was 14.08% among middle-aged and older patients with dyslipidaemia and was correlated with demographic factors, multimorbidity, and health service preferences in China. These findings suggest the need to integrate patient-specific factors into CHM-based dyslipidaemia management strategies.